February 27, 2015 4:21 PM ET


Company Overview of InnoPharma, Inc.

Company Overview

InnoPharma, Inc., a sterile product development company, engages in the development of generic and specialty pharmaceutical products in the form of pen and depot injectables, and ophthalmic dosage. It offers therapeutic drugs for respiratory, anti-cancer, anti-viral, hormones, critical care, CNS, anti-psychotic, and anti-arrhythmic categories; and vitamin D injections, and antagonist tablets. It also develops formulations, which include solutions, suspensions, lyophilized, emulsions, liposomes, micelles, and lipid complexes; small molecules with solubility and stability challenges; polypeptides and carbohydrates; and novel formulations of existing drugs, including hard-to-make products in th...

10 Knightsbridge Road

Piscataway, NJ 08854

United States

Founded in 2005





Key Executives for InnoPharma, Inc.

Founder, Vice President of Pharmaceutical Science and Director
Co-Founder, Operating Officer and Executive Director
Senior Director of Finance
Age: 50
Scientific Officer and Executive Director
Vice President of Business Development & Alliance Management
Compensation as of Fiscal Year 2014.

InnoPharma, Inc. Key Developments

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN

InnoPharma Inc. announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN(R). InnoPharma developed the generic formulation of decitabine for injection and entered into an agreement with Sandoz Inc., pursuant to which Sandoz will sell, market and distribute decitabine for injection in the United States. According to IMS data, aggregate U.S. sales of DACOGEN were approximately $251 million for the twelve months ending in April 2014. Decitabine for injection is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection will be marketed in 20 mL single dose glass vials containing 50 mg decitabine, the same size and strength as the brand. The dosing regimen is identical to the brand.

Sandoz Canada to Make, Use, Sell, Market and Distribute InnoPharma's Olanzapine Injection in Canada

InnoPharma Inc. announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa(R) injection), in Canada. Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania. As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada.

InnoPharma, LLC Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 08:00 AM

InnoPharma, LLC Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 08:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Navneet Puri, Founder, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
CIBA Vision Ophthalmics Inc. United States
Arisaph Pharmaceuticals, Inc. United States
OPKO Ophthalmics, LLC United States
AstraZeneca LP United States
Charisela Technologies, Inc. United States

Recent Private Companies Transactions

July 16, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact InnoPharma, Inc., please visit innopharmainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.